Imugene Limited Launches Major Share Placement to Support Azer-cel Clinical Progress

3 min read | July 07, 2026 10:12 AM AEST | By Anjali Anand

Imugene Limited Launches Major Share Placement to Support Azer-cel Clinical Progress

Key Points

Company: Imugene Limited (ASX:IMU)
Proposed issuance of 117,052,638 fully paid ordinary shares
Share issue price set at AUD 0.095 per share
Shareholder approval required for part of the placement; vote scheduled for 18 August 2026

Overview of the Share Placement

Imugene Limited announced a substantial share placement involving 117,052,638 fully paid ordinary shares, divided into two tranches. Tranche 1 will be issued under the company’s existing placement capacity per ASX Listing Rules 7.1 and 7.1A, while Tranche 2 requires shareholder approval. The planned issue date is 13 July 2026.

The shares are priced at AUD 0.095 each, designed to attract institutional and sophisticated investors, facilitating efficient capital raising with minimal execution risk.

Tranche Breakdown and Shareholder Approval Process

Tranche 1 comprises approximately 73.7 million shares allocated to institutional and sophisticated investors, proceeding without the need for shareholder consent by utilizing existing ASX placement capacity.

Tranche 2 involves roughly 43.4 million shares issued to select investors, including company directors, and is subject to shareholder approval at the meeting scheduled for 18 August 2026. This approval is critical to complete the full placement.

Allocation of Raised Funds

Proceeds from the placement will advance Imugene’s lead asset, azer-cel, by supporting essential clinical trials, regulatory submissions, and manufacturing milestones. Additionally, a portion of the funds will be allocated for general working capital needs.

This funding strategy highlights Imugene’s focus on pipeline progression and enhancing shareholder value through targeted investment in core assets.

Placement Strategy Rationale

Imugene selected a placement approach over a pro-rata issue or security purchase plan to rapidly access capital from institutional and sophisticated investors, minimizing transaction costs and execution risks. This method ensures timely funding to support strategic initiatives related to azer-cel without delay.

Lead Manager and Associated Fees

Bell Potter Securities Limited has been appointed as lead manager and bookrunner for the placement. Management fees include 0.75% of total global proceeds and 5.25% of proceeds from investors in Australia, New Zealand, and Asia.

Estimated total expenses for the offer, covering ASX fees, accounting, legal, and other costs, are approximately AUD 0.8 million, integral to the successful execution of the capital raise.

Regulatory Compliance and Shareholder Communication

Imugene commits to full regulatory compliance, including issuing a cleansing notice under the Corporations Act to facilitate resale of new securities within 12 months post-issue.

All newly issued shares will rank equally with existing shares, ensuring fairness and consistency for all shareholders involved.

Next Steps and Investor Guidance

Investors should watch for the extraordinary general meeting where shareholder approval for Tranche 2 will be determined on 18 August 2026. This decision is crucial for the full placement completion.

Monitoring the progress of azer-cel’s clinical and regulatory milestones is advisable, as positive developments could significantly influence Imugene’s market position and valuation.

Market Impact and Share Price Outlook

Immediate share price effects remain unclear from public data. However, successful placement execution and advancements in azer-cel’s development may positively affect market sentiment and investor confidence.

Ongoing communication regarding strategic initiatives and financial health will be key for investors assessing Imugene’s long-term growth potential and clinical achievements.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.